Transaction DateRecipientSharesTypePriceValue
24th January 2019Terri B Sebree3,600Grant/award etc.$0.00
Zynerba Pharmaceuticals
Zynerba Pharmaceuticals logo

Zynerba Pharmaceuticals, Inc. engages in the development and commercialization of transdermal pharmaceutically-produced cannabinoid treatments. The company was founded by Audra L. Stinchcomb on January 31, 2007 and is headquartered in Devon, PA.

Ticker: ZYNE
Sector: Health Technology
Industry: Pharmaceuticals: Other
SEC Central Index Key (CIK): 1621443
Employees: 28
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $77 M (9%)
Other Assets, Current: $284 Th (-26%)
Assets, Current: $85 M (-1%)
Property, Plant and Equipment, Net: $641 Th (0%)
Assets: $87 M (0%)
Accounts Payable, Current: $4 M (-18%)
Accrued Liabilities, Current: $9 M (0%)
Liabilities, Current: $13 M (8%)
Liabilities: $13 M (7%)
Common Stock, Value, Issued: $29 Th (26%)
Common Stock, Shares, Issued: $29 M (26%)
Retained Earnings (Accumulated Deficit): $184 M (0%)
Stockholders' Equity (Parent): $74 M (0%)
Liabilities and Equity: $87 M (0%)
Research and Development: $17 M (-28%)
General and Administrative Expenses: $4 M (-46%)
Operating Income/Loss: $22 M (-33%)
Other Income, net: $2 M (5041%)